1. Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016;41:211-8.

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.

3. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142-50.

4. Handschuh L, Kazmierczak M, Milewski MC, Goralski M, Luczak M, et al. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol 2018;52:656-78.

5. Beckner ME, Fellows-Mayle W, Zhang Z, Agostino NR, Kant JA, et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer 2010;126:2282-95.

6. Song Y, Luo Q, Long H, Hu Z, Que T, et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer 2014;13:65.

7. Cecconi D, Carbonare LD, Mori A, Cheri S, Deiana M, et al. An integrated approach identifies new oncotargets in melanoma. Oncotarget 2018;9:11489-502.

8. Ludvigsen M, Bjerregard Pedersen M, Lystlund Lauridsen K, Svenstrup Poulsen T, Hamilton-Dutoit SJ, et al. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. Blood Adv 2018;2:2533-42.

9. Cancemi P, Buttacavoli M, Roz E, Feo S. Expression of alpha-enolase (ENO1), myc promoter-binding protein-1 (MBP-1) and matrix metalloproteinases (MMP-2 and MMP-9) reflect the nature and aggressiveness of breast tumors. Int J Mol Sci 2019;20.

10. Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2010;121:539-53.

11. Zhan P, Zhao S, Yan H, Yin C, Xiao Y, et al. alpha-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer. Mol Carcinog 2017;56:1427-37.

12. Zhao M, Fang W, Wang Y, Guo S, Shu L, et al. Enolase-1 is a therapeutic target in endometrial carcinoma. Oncotarget 2015;6:15610-27.

13. Qiao H, Wang Y, Zhu B, Jiang L, Yuan W, et al. Enolase1 overexpression regulates the growth of gastric cancer cells and predicts poor survival. J Cell Biochem 2019;120:18714-23.

14. Zhou X, Yao K, Zhang L, Zhang Y, Han Y, et al. Identification of differentiation-related proteins in gastric adenocarcinoma tissues by proteomics. Technol Cancer Res Treat 2016;15:697-706.

15. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, et al. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010;46:1712-23.

16. Zhu W, Li H, Yu Y, Chen J, Chen X, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res 2018;10:5735-45.

17. Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol 2015;8:22.

18. Racz A, Brass N, Hofer M, Sybrecht GW, Remberger K, et al. Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. Int J Oncol 2000;17:67-73.

19. Cruz IN, Coley HM, Kramer HB, Madhuri TK, Safuwan NA, et al. Proteomics analysis of ovarian cancer cell lines and tissues reveals drug resistance-associated proteins. Cancer Genomics Proteomics 2017;14:35-51.

20. Yin H, Wang L, Liu HL. ENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance. Gastroenterol Res Pract 2018;2018:3842198.

21. Sun L, Guo C, Cao J, Burnett J, Yang Z, et al. Over-expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer. Int J Med Sci 2017;14:655-61.

22. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer 2009;125:639-48.

23. Marangos PJ, Parma AM, Goodwin FK. Functional properties of neuronal and glial isoenzymes of brain enolase. J Neurochem 1978;31:727-32.

24. Kang HJ, Jung SK, Kim SJ, Chung SJ. Structure of human alpha-enolase (hENO1), a multifunctional glycolytic enzyme. Acta Crystallogr D Biol Crystallogr 2008;64:651-7.

25. Brewer JM. Yeast enolase: mechanism of activation by metal ions. CRC Crit Rev Biochem 1981;11:209-54.

26. Petrak J, Ivanek R, Toman O, Cmejla R, Cmejlova J, et al. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 2008;8:1744-9.

27. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002;82:1524-32.

28. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, et al. Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer’s disease and mild cognitive impairment: implications for progression of AD. J Proteome Res 2009;8:471-82.

29. Butterfield DA, Lange ML. Multifunctional roles of enolase in Alzheimer’s disease brain: beyond altered glucose metabolism. J Neurochem 2009;111:915-33.

30. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421-9.

31. Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M, Mera-Varela A, et al. Particular association of clinical and genetic features with autoimmunity to citrullinated alpha-enolase in rheumatoid arthritis. Arthritis Rheum 2011;63:654-61.

32. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12:340-54.

33. Terrier B, Tamby MC, Camoin L, Guilpain P, Berezne A, et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010;69:428-33.

34. Bergmann S, Schoenen H, Hammerschmidt S. The interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells. Int J Med Microbiol 2013;303:452-62.

35. Funk J, Schaarschmidt B, Slesiona S, Hallstrom T, Horn U, et al. The glycolytic enzyme enolase represents a plasminogen-binding protein on the surface of a wide variety of medically important fungal species. Int J Med Microbiol 2016;306:59-68.

36. Li M, Li J, Wang J, Li Y, Yang P. Serum level of anti-alpha-enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer. Lupus 2018;27:139-42.

37. Peng B, Huang X, Nakayasu ES, Petersen JR, Qiu S, et al. Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis. J Proteome Res 2013;12:1789-96.

38. Zhang B, Wang Z, Deng B, Wu X, Liu J, et al. Identification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics. Proteome Sci 2013;11:30.

39. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 2000;473:47-52.

40. Bae SM, Min HJ, Ding GH, Kwak SY, Cho YL, et al. Protein expression profile using two-dimensional gel analysis in squamous cervical cancer patients. Cancer Res Treat 2006;38:99-107.

41. Katayama M, Nakano H, Ishiuchi A, Wu W, Oshima R, et al. Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today 2006;36:1085-93.

42. Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 2003;9:3641-4.

43. Duijvesz D, Burnum-Johnson KE, Gritsenko MA, Hoogland AM, Vredenbregt-van den Berg MS, et al. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS One 2013;8:e82589.

44. Seweryn E, Pietkiewicz J, Bednarz-Misa IS, Ceremuga I, Saczko J, et al. Localization of enolase in the subfractions of a breast cancer cell line. Z Naturforsch C J Biosci 2009;64:754-8.

45. He P, Naka T, Serada S, Fujimoto M, Tanaka T, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 2007;98:1234-40.

46. Mears R, Craven RA, Hanrahan S, Totty N, Upton C, et al. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 2004;4:4019-31.

47. Greening DW, Ji H, Chen M, Robinson BW, Dick IM, et al. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Sci Rep 2016;6:32643.

48. Pan D, Chen J, Feng C, Wu W, Wang Y, et al. Preferential localization of MUC1 glycoprotein in exosomes secreted by non-small cell lung carcinoma cells. Int J Mol Sci 2019;20.

49. Valcz G, Galamb O, Krenacs T, Spisak S, Kalmar A, et al. Exosomes in colorectal carcinoma formation: ALIX under the magnifying glass. Mod Pathol 2016;29:928-38.

50. Didiasova M, Schaefer L, Wygrecka M. When place matters: shuttling of enolase-1 across cellular compartments. Front Cell Dev Biol 2019;7:61.

51. Entelis N, Brandina I, Kamenski P, Krasheninnikov IA, Martin RP, et al. A glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae. Genes Dev 2006;20:1609-20.

52. Brandina I, Graham J, Lemaitre-Guillier C, Entelis N, Krasheninnikov I, et al. Enolase takes part in a macromolecular complex associated to mitochondria in yeast. Biochim Biophys Acta 2006;1757:1217-28.

53. Gao S, Li H, Cai Y, Ye JT, Liu ZP, et al. Mitochondrial binding of alpha-enolase stabilizes mitochondrial membrane: its role in doxorubicin-induced cardiomyocyte apoptosis. Arch Biochem Biophys 2014;542:46-55.

54. Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW. Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 1995;270:27752-7.

55. Plow EF, Das R. Enolase-1 as a plasminogen receptor. Blood 2009;113:5371-2.

56. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27:441-64.

57. Liu Y, Li H, Liu Y, Zhu Z. MiR-22-3p targeting alpha-enolase 1 regulates the proliferation of retinoblastoma cells. Biomed Pharmacother 2018;105:805-12.

58. Zhu X, Yu H, Li B, Quan J, Zeng Z, et al. Targetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma. Biosci Rep 2019;39.

59. Ji M, Wang Z, Chen J, Gu L, Chen M, et al. Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating beta-catenin. Biosci Rep 2019;39.

60. Sun L, Lu T, Tian K, Zhou D, Yuan J, et al. Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway. Eur J Pharmacol 2019;845:8-15.

61. Liu YQ, Huang ZG, Li GN, Du JL, Ou YP, et al. Effects of alpha-enolase (ENO1) over-expression on malignant biological behaviors of AGS cells. Int J Clin Exp Med 2015;8:231-9.

62. Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, et al. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget 2016;7:5598-612.

63. Chen S, Zhang Y, Wang H, Zeng YY, Li Z, et al. WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma. Cell Death Dis 2018;9:347.

64. Qiao H, Wang YF, Yuan WZ, Zhu BD, Jiang L, et al. Silencing of ENO1 by shRNA inhibits the proliferation of gastric cancer cells. Technol Cancer Res Treat 2018;17:1533033818784411.

65. Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012;92:509-19.

66. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 1995;227:407-15.

67. Chen X, Xu H, Wu N, Liu X, Qiao G, et al. Interaction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells. Oncotarget 2017;8:30305-16.

68. Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, et al. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol 2017;10:16.

69. Su S, Xu H, Chen X, Qiao G, Farooqi AA, et al. CS5931, A novel marine polypeptide, inhibits migration and invasion of cancer cells via interacting with enolase 1. Recent Pat Anticancer Drug Discov 2018;13:360-7.

70. Yu L, Shi J, Cheng S, Zhu Y, Zhao X, et al. Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. Mol Endocrinol 2012;26:1521-30.

71. Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, et al. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget 2015;6:11098-113.

72. Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, et al. Surface alpha-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. PLoS One 2013;8:e69354.

73. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 2006;12:5746-54.

74. Dai L, Qu Y, Li J, Wang X, Wang K, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer. Oncotarget 2017;8:36664-73.

75. Qin J, Wang S, Shi J, Ma Y, Wang K, et al. Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma. Cancer Sci 2019;110:1829-41.

76. Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010;7:17-23.

77. Cui JW, Li WH, Wang J, Li AL, Li HY, et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 2005;4:1718-24.

78. Zou L, Wu Y, Pei L, Zhong D, Gen M, et al. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res 2005;29:1387-91.

79. Forgber M, Trefzer U, Sterry W, Walden P. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One 2009;4:e5199.

80. Kondo H, Sahara H, Miyazaki A, Nabeta Y, Hirohashi Y, et al. Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells. Jpn J Cancer Res 2002;93:917-24.

81. Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology 2013;144:1098-106.

82. Yang M, Sun Y, Sun J, Wang Z, Zhou Y, et al. Differentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis. Cancer Med 2018;7:1081-92.

83. Zhou H, Chen CB, Lan J, Liu C, Liu XG, et al. Differential proteomic profiling of chordomas and analysis of prognostic factors. J Surg Oncol 2010;102:720-7.

84. White-Al Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, et al. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. Clin Exp Metastasis 2015;32:531-41.

85. Hsiao KC, Shih NY, Chu PY, Hung YM, Liao JY, et al. Anti-alpha-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget 2015;6:35073-86.

86. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, et al. Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011;10:105-12.

87. Niccolai E, Cappello P, Taddei A, Ricci F, D’Elios MM, et al. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Int J Oncol 2016;49:393-401.

88. Shih NY, Lai HL, Chang GC, Lin HC, Wu YC, et al. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol 2010;40:663-9.

89. Zhang L, Wang H, Dong X. Diagnostic value of alpha-enolase expression and serum alpha-enolase autoantibody levels in lung cancer. J Bras Pneumol 2018;44:18-23.

90. Griggio V, Mandili G, Vitale C, Capello M, Macor P, et al. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 2017;8:3274-88.

91. Yu YQ, Wang L, Jin Y, Zhou JL, Geng YH, et al. Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. Oncotarget 2016;7:16362-71.

92. Fortunato S, Bononi G, Granchi C, Minutolo F. An update on patents covering agents that interfere with the cancer glycolytic cascade. ChemMedChem 2018;13:2251-65.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: